Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.
about
Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer.SOD2 deregulation enhances migration, invasion and has poor prognosis in salivary adenoid cystic carcinomamiR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2The Zuo Jin Wan Formula Induces Mitochondrial Apoptosis of Cisplatin-Resistant Gastric Cancer Cells via Cofilin-1.Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling.GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer.MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell.Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/β-Catenin pathway.REC8 inhibits EMT by downregulating EGR1 in gastric cancer cells.14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo.Metabolic vulnerability of cisplatin-resistant cancers
P2860
Q33618553-2AE27E92-2D55-4BFD-8724-FDF47BD57C3BQ36903196-A196EB27-99CB-43F5-89DD-F4EBF60F0949Q36950630-8EAB1038-9BFC-4D06-B3E4-CB29E9D3EE98Q37410822-EF2B7A7F-C418-4FDE-B9D8-F9D19C1BFD6BQ37642507-FF4D2008-0FF5-4670-A45D-EFCA25796812Q37748056-4C7F6F02-B72F-42D8-8638-2C570A5EF229Q38630252-75FDA0CD-2B85-420C-9008-0E63AB44F72FQ39281229-010BF532-07E3-4F2C-9256-89EFE0ED1CD1Q41069109-96F663EF-333E-4ABE-B2E7-923AC4174CD3Q48806131-77509411-3415-4E72-A131-60043F7995B6Q49165446-B520DEE2-0465-498B-BCF7-750BBBC4024CQ49378805-CA34347B-04F9-465C-8BEC-3A068A48328CQ49397656-5F7B26B3-7CDF-4675-B620-9AB67B1222B5Q49469993-AB9D4C3B-B6A5-43DB-BD4D-25E2F1B128F4Q50133239-844158E4-2EA8-4E10-83A3-FF9147B861C8Q55286461-393D3AF3-2D56-4AED-812F-5F2714D94D16Q58416980-C384E3BC-8FB4-4C1F-8AFE-83F7C3250E6D
P2860
Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cisplatin resistance in gastri ...... helial-mesenchymal transition.
@ast
Cisplatin resistance in gastri ...... helial-mesenchymal transition.
@en
type
label
Cisplatin resistance in gastri ...... helial-mesenchymal transition.
@ast
Cisplatin resistance in gastri ...... helial-mesenchymal transition.
@en
prefLabel
Cisplatin resistance in gastri ...... helial-mesenchymal transition.
@ast
Cisplatin resistance in gastri ...... helial-mesenchymal transition.
@en
P2093
P2860
P356
P1433
P1476
Cisplatin resistance in gastri ...... helial-mesenchymal transition.
@en
P2093
Chengchao Shou
Dongsheng Huang
Guoqing Ru
Hongying Duan
Xiangmin Tong
Zhongsheng Zhao
P2860
P2888
P356
10.1038/SREP20502
P407
P577
2016-02-05T00:00:00Z